PD173955

PD173955 is an orally active inhibitor of Src (IC50= 22 nM), Yes, Abl, ATP and MAP kinases. PD173955 can effectively prevent the mitotic process and has anticancer activity[1][2][3][4].

Product Specifications

CAS Number

[260415-63-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bcr-Abl; Src

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PD173955.html

Purity

99.12

Solubility

DMSO : 10 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

O=C1C(C2=C(Cl)C=CC=C2Cl)=CC3=CN=C(NC4=CC=CC(SC)=C4)N=C3N1C

Molecular Formula

C21H16Cl2N4OS

Molecular Weight

443.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Moasser MM, et al. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 1999 Dec 15;59 (24) :6145-52. PMID: 10626805.|[2]Martinelli G, et al. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia. 2005 Nov;19 (11) :1872-9. |[3]Netzer WJ, et al. Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage. Proc Natl Acad Sci U S A. 2017 Feb 7;114 (6) :1389-1394. |[4]Wolff NC, et al. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood. 2005 May 15;105 (10) :3995-4003.